Challenging Relapse and Refractory Marginal Zone Lymphoma with CAR T-cell Therapy: A Systemic Analysis of Treatment Options and Outcomes
Original framing: “[Comment] CAR T-cell therapy for patients with relapsed or refractory marginal zone lymphoma” — The Lancet
CAR T-cell therapy has shown significant promise in treating relapsed or refractory marginal zone lymphoma, with high response rates and durable remissions. However, the efficacy of this treatment must be contextualized within the broader structural patterns of healthcare access and patient demographics. Score: 0.9
The use of CAR T-cell therapy in relapsed or refractory marginal zone lymphoma reflects a Western biomedical paradigm that prioritizes technological innovation over cultural and spiritual contexts.
However, this narrative neglects to address the structural barriers to access and the socioeconomic determinants of health outcomes. To address these gaps, healthcare systems must prioritize equitable distribution of benefits and risks across diverse patient populations, integrate traditional knowledge and practices into modern cancer treatment, and address the structural causes of healthcare disparities. By taking a holistic and systemic approach to cancer treatment, we can improve health outcomes and promote more equitable healthcare systems.